logo-loader
viewNaturally Splendid Enterprises Ltd.

Naturally Splendid Enterprises updates on clinical trial application for Cavaltinib to treat coronavirus

Cavaltinib is licensed to a joint venture owned by Naturally Splendid and Biologic Pharmamedical Research

Naturally Splendid Enterprises Ltd. -
The drug candidate has been shown to inhibit IL-6 and several other cytokines central to the 'cytokine storm' phenomenon

Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCMKTS:NSPDF) has revealed that it is submitting further information to Health Canada as part of its fast-track application for a Phase 2 trial of Cavaltinib to treat coronavirus (COVID-19).

The group also said it has now submitted the clinical trial design protocol through the proposed joint venture with Biologic Pharmamedical Research. Cavaltinib is licensed to a joint venture owned by Naturally Splendid and Biologic Pharmamedical Research based on technology and patents developed by Biologic.

READ: Naturally Splendid updates investors on Health Canada application for Phase 2 Cavaltinib trial for coronavirus

The candidate has been shown to inhibit IL-6 and several other cytokines central to the 'cytokine storm' phenomenon, where the body starts to attack its own cells rather than just fighting off the virus, seen in critically ill COVID-19 patients.

Naturally Splendid noted that data from the research of this patented technology associated with Cavaltinib was consistent with treatment protocols that medical experts believe will offer effective treatment for coronavirus patients.

"This has been an eighteen-year journey for me," said Franco Cavaleri, the researcher from Biologic Pharmamedical responsible for these discoveries in a statement.

"The discoveries made with this technology were made long before our COVID-19 crisis. While we have put this pharmacology to good use in the human population to treat other ailments, this novel variant of the drug may serve an even bigger impact on human health and wellness in the battle against COVID-19."

Cavaltinib may also serve as a prophylactic measure in the future as we face other similar threats, Naturally Splendid said.

"The world has evolved to a population density and reach that presents the conditions for virus species jumping and efficient transmission of infection. While research treatment options for today's crisis remain the shorter-term need, it must be kept in mind how this proposed treatment model can serve us in the future," the health food-focused firm added.

Shares in Toronto advanced 10% to C$0,055.

Contact the author at [email protected]

Quick facts: Naturally Splendid Enterprises Ltd.

Price: 0.055 CAD

TSX-V:NSP
Market: TSX-V
Market Cap: $10.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Naturally Splendid Enterprises Ltd. named herein, including the promotion by the Company of Naturally Splendid Enterprises Ltd. in any Content...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Naturally Splendid passes audit to maintain its Safe Quality Food Level 2...

Naturally Splendid (CVE: NSP-OTC: NSPDF) CEO Craig Goodwin joined Steve Darling from Proactive Vancouver to discuss the company once again passing their annual audit that certifies their Pitt Meadows, BC operation as a Safe Quality Food Level 2 certified food manufacturing facility. Goodwin...

4 days, 23 hours ago

2 min read